Patents

AXM Pharma Enters Into Representation Agreement with Leading Pharmaceutical Company

Published in Lab Business Week, October 21st, 2007

AXM Pharma (OTC: AXMP) announced that it has entered into an exclusive representation agreement with Xian Jiahui Pharma Co., Ltd., a leading Chinese pharmaceutical manufacturer. Under this agreement, AXM Pharma will represent Xian Jiahui in the sale of new medicines, including its patent-pending Shen Kang injection/suppository. AXM sold approximately $375,000 worth of product in the first day of sales.

Shen Kang injection/suppository is the only Chinese traditional medicine compound dosage that can prevent and cure chronic allograft nephropathy (CAN). Transplanted nephridium of CAN has a low survivability. Most patients will get CAN after one or two years, which causes...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2007-10-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry